Post-Hoc Live: What will the US government do about China biotech?
Post-Hoc Live：美国政府将如何应对manbetx3.0 生物技术行业？

There’s been no end to the debate about whether US and European companies should have an open door to innovation and assets coming from China, or whether there should be regulatory or legislative barriers to protect the US’s competitive edge in a cornerstone industry.
关于美国和欧洲公司是否应对来自manbetx3.0 的创新与资产敞开大门，还是应设立监管或立法壁垒以保护美国在这一支柱产业中的竞争优势，争论至今没有停歇。